Education
About Us
Working with TipRanks
Follow Us
Simulations Plus (SLP)
NASDAQ:SLP
SLP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.39 - $37.67
Previous CloseN/A
Volume738.72K
Average Volume (3M)494.71K
Market Cap
$285.20M
Enterprise Value$612.77M
Total Cash (Recent Filing)$28.45M
Total Debt (Recent Filing)$719.00K
Price to Earnings (P/E)47.5
Beta1.13
Next Earnings
Oct 22, 2025EPS Estimate
0.06Last Dividend Ex-Date
Jul 29, 2024Dividend Yield0.42%
Share Statistics
EPS (TTM)0.45
Shares Outstanding20,127,110
10 Day Avg. Volume365,721
30 Day Avg. Volume494,714
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.15
Enterprise Value/Revenue7.62
Enterprise Value/Gross Profit14.18
Enterprise Value/Ebitda-9.00
Forecast
1Y Price Target
$25.25Price Target Upside78.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
EarningsSimulations Plus reported revenue and adjusted EBITDA that exceeded consensus estimates, showing a decent financial performance.
Financial PerformanceSimulations Plus reported revenue of $22.4 million, outperforming estimates due to better-than-expected software and service sales.
Strategic PositioningThe transition from traditional animal testing to biosimulation and modeling positions SLP well for long-term growth.
Bears Say
Demand ConcernsRenewal rates have dropped significantly on both an account and fee basis, indicating potential softening as the company heads into fiscal 2026.
Guidance And EstimatesSimulations Plus announced preliminary third quarter fiscal 2025 revenue and updated its fiscal 2025 revenue guidance range, which is well below expectations.
Market ChallengesBiopharma clients are reducing budgets, canceling work, and delaying projects due to market uncertainty over future funding, drug pricing, and potential tariffs.
Simulations Plus News
SLP FAQ
What was Simulations Plus’s price range in the past 12 months?
Simulations Plus lowest stock price was $12.39 and its highest was $37.66 in the past 12 months.
What is Simulations Plus’s market cap?
Simulations Plus’s market cap is $285.20M.
When is Simulations Plus’s upcoming earnings report date?
Simulations Plus’s upcoming earnings report date is Oct 22, 2025 which is in 51 days.
How were Simulations Plus’s earnings last quarter?
Simulations Plus released its earnings results on Jul 14, 2025. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.207 by $0.243.
Is Simulations Plus overvalued?
According to Wall Street analysts Simulations Plus’s price is currently Undervalued.
Does Simulations Plus pay dividends?
Simulations Plus pays a Quarterly dividend of $0.06 which represents an annual dividend yield of 0.42%. See more information on Simulations Plus dividends here
What is Simulations Plus’s EPS estimate?
Simulations Plus’s EPS estimate is 0.06.
How many shares outstanding does Simulations Plus have?
Simulations Plus has 20,127,110 shares outstanding.
What happened to Simulations Plus’s price movement after its last earnings report?
Simulations Plus reported an EPS of $0.45 in its last earnings report, beating expectations of $0.207. Following the earnings report the stock price went down -25.758%.
Which hedge fund is a major shareholder of Simulations Plus?
Currently, no hedge funds are holding shares in SLP
Simulations Plus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.25 (78.19% Upside)
$25.25 (78.19% Upside)
Blogger Sentiment
Bullish
SLP Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 74.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.88%
12-Months-Change
Fundamentals
Return on Equity
-41.49%
Trailing 12-Months
Asset Growth
-30.27%
Trailing 12-Months
Company Description
Simulations Plus
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
SLP Company Deck
SLP Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While the company reported positive revenue growth and improvements in adjusted EBITDA, significant challenges such as organic revenue decline, large net loss due to impairment, and substantial market headwinds contribute to a mixed outlook. The strategic reorganization and AI-driven initiatives are promising, but the impact of these efforts remains to be seen.View all SLP earnings summariesSLP Stock 12 Month Forecast
Average Price Target
$25.25
▲(78.19% Upside)
Technical Analysis
Ownership Overview
17.35% Insiders
27.98% Mutual Funds
24.12% Other Institutional Investors
13.17% Public Companies and
Individual Investors